Department of Otolaryngology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Endoscopic Nasal and Sinus Surgery Excellence Center, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Asian Pac J Allergy Immunol. 2020 Sep;38(3):162-169. doi: 10.12932/AP-210520-0853.
Olfactory and gustatory dysfunctions (OGD) are pathognomonic symptoms in patients with Coronavirus Disease 2019 (COVID-19). This study reviews the associations of OGD with COVID-19 which will be useful for early diagnosis and self-isolation. Systematic searches of PubMed, Ovid Medline, Scopus, and EMBASE electronic databases were performed. Studies reporting OGD in COVID-19 patients were included. Data were pooled for meta-analysis. The outcomes were odds ratios (OR) of OGD in COVID-19 patients. Proportions of smell and/or taste dysfunctions in the COVID-19 patients were assessed. Fourteen studies (21,515 participants, age 49.12 years, 26% male) were included. The OR of olfactory and/or gustatory dysfunctions in COVID-19 patients were 11.26 (95% confidence interval (CI) 5.41 to 23.4) when compared with acute respiratory infection (ARI) without detectable virus and 6.46 (95% CI 2.79 to 14.97) in patients with other respiratory viruses. The OR of olfactory dysfunction in COVID-19 patients were 11.67 (95% CI 6.43 to 21.17) when compared with the ARI patients without detectable virus and 4.17 (95% CI 1.34 to 12.98) with other respiratory viruses. The OR of gustatory dysfunction in COVID-19 patients were 12.70 (95% CI 7.9 to 20.44) when compared with the ARI patients without detectable virus and 4.94 (95%CI 1.59 to 15.31) with other respiratory viruses. Fifty percent (95% CI 36.7 to 63.3%) of COVID-19 patients had olfactory and/or gustatory dysfunctions. In summary, there are associations between OGD and COVID-19 patients. Patients presenting with ARI should be assessed for olfactory and gustatory functions.
嗅觉和味觉障碍(OGD)是 2019 年冠状病毒病(COVID-19)患者的特征性症状。本研究综述了 OGD 与 COVID-19 的关联,这对于早期诊断和自我隔离将是有用的。系统检索了 PubMed、Ovid Medline、Scopus 和 EMBASE 电子数据库。纳入了报告 COVID-19 患者 OGD 的研究。对数据进行汇总进行荟萃分析。结果为 COVID-19 患者 OGD 的比值比(OR)。评估 COVID-19 患者嗅觉和/或味觉障碍的比例。纳入了 14 项研究(21515 名参与者,年龄 49.12 岁,26%为男性)。与急性呼吸道感染(ARI)无病毒可检测相比,COVID-19 患者嗅觉和/或味觉障碍的 OR 为 11.26(95%置信区间(CI)5.41 至 23.4),与其他呼吸道病毒相比为 6.46(95%CI 2.79 至 14.97)。与无病毒可检测的 ARI 患者相比,COVID-19 患者嗅觉障碍的 OR 为 11.67(95%CI 6.43 至 21.17),与其他呼吸道病毒相比为 4.17(95%CI 1.34 至 12.98)。与无病毒可检测的 ARI 患者相比,COVID-19 患者味觉障碍的 OR 为 12.70(95%CI 7.9 至 20.44),与其他呼吸道病毒相比为 4.94(95%CI 1.59 至 15.31)。50%(95%CI 36.7 至 63.3%)的 COVID-19 患者存在嗅觉和/或味觉障碍。总之,OGD 与 COVID-19 患者之间存在关联。出现 ARI 的患者应评估嗅觉和味觉功能。